Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Phase 2
Completed
- Conditions
- CancerRenal Cell Carcinoma
- Interventions
- Drug: recombinant interleukin-21
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT00617253
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Nijmegen, Netherlands
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 178
- Registration Number
- NCT00614055
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valladolid, Spain
Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 182
- Registration Number
- NCT00613951
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, San Juan, Spain
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 929
- Registration Number
- NCT00614120
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Suwon, Korea, Republic of
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 178
- Registration Number
- NCT00612040
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Umeå, Sweden
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 75
- Registration Number
- NCT00612599
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 245
- Registration Number
- NCT00611884
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa
Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 241
- Registration Number
- NCT00604656
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Wroclaw, Poland
Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 193
- Registration Number
- NCT00605111
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 719
- Registration Number
- NCT00605020
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
© Copyright 2025. All Rights Reserved by MedPath